Core to Hikma’s strategy is having a strong local presence in our markets.
We have an extensive network of manufacturing facilities across the US, MENA and Europe and are continually expanding this presence by building new sites and expanding existing ones. Through our local sites, we are uniquely positioned to respond quickly to evolving healthcare needs and priorities and to ensure greater reliability of supply.
1. IQVIA MAT through November 2023, includes all generic injectable and non-injectables
2. Branded. Based on internal analysis by Hikma using IQVIA MIDAS® Monthly value sales data for Kuwait, KSA, UAE, Jordan, Lebanon, Egypt, Tunisia, Algeria and Morocco, MAT Dec 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.